📰 Abstract Code News
Page 2 - Abstract Code News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Abstract Code. Real-time updates on events, politics, business and more.
June 10, 2022
Announces an update from the LYMRIT 37-05 Phase 1 trial investigating Betalutin® (177Lu lilotomab...
June 10, 2022
Data supports further development of CYT-338 in relapsed/refractory multiple myeloma
May 18, 2022
/PRNewswire/ -- Cytovia Therapeutics, LLC ("Cytovia Therapeutics"), a global biotechnology company focused on harnessing the power of natural killer (NK) cells...
May 13, 2022
/PRNewswire/ -- Dizal (SSE: 688192) will present the data from an ongoing phase I/II study of golidocitnib, a selective JAK1 inhibitor, in refractory or...
May 12, 2022
Investegate announcements from Syncona Limited, Autolus to present clinical data at EHA Congress
May 12, 2022
- AUTO4: oral presentation on initial clinical experience in peripheral T cell lymphoma- AUTO1/22: oral presentation on initial experience in r/r pediatric...
May 12, 2022
12.05.2022 - Clinical Updates for HM43239 and Luxeptinib Poster Presentation for HM43239 is Scheduled for June 10th at EHA2022 Hybrid Congress SAN DIEGO and TORONTO, May 12, 2022 (GLOBE NEWSWIRE) - Aptose Biosciences Inc. (“Aptose” or the “Company”) ...
May 27, 2021
Clinical Updates for Luxeptinib in AML & B-cell Cancers and for APTO-253 in AML & MDS Poster Presentations for CG-806 and APTO-253 are Scheduled for June 11th at EHA2021... | May 27, 2021